Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Verrica Pharmaceuticals Inc. VRCA

Healthcare  —  Biotechnology
4.37 0.01 0.23% as of 25 Sep
Market cap
$74.9M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Verrica Pharmaceuticals Inc. (VRCA) Business Profile

Updated before January 2025

Company Overview

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) is a clinical-stage dermatology therapeutics company focused on developing and commercializing innovative treatments for skin diseases. Founded in 2013 and headquartered in West Chester, Pennsylvania, Verrica aims to address unmet needs in dermatology by leveraging its expertise in drug development and regulatory processes. The company is led by a team of experienced professionals, including its President and CEO, Ted White, who has extensive experience in the pharmaceutical and biotechnology sectors. Verrica’s leadership team also includes key executives such as Christopher Degnan, Chief Financial Officer, and Dr. Gary Goldenberg, Chief Medical Officer, who bring a wealth of knowledge in dermatology and clinical research.

Core Business Segments

Verrica Pharmaceuticals focuses on developing treatments for dermatological conditions, with its primary emphasis on non-systemic therapies. The company’s core business segments include:

1. Dermatology Therapeutics

  • VP-102 (Ycanth™): Verrica’s lead product candidate, VP-102, is a proprietary drug-device combination designed for the treatment of molluscum contagiosum, a highly contagious viral skin infection that primarily affects children. VP-102 has completed Phase 3 clinical trials and is awaiting regulatory approval.
  • VP-103: Another product candidate in Verrica’s pipeline, VP-103, is being developed for the treatment of common warts. It utilizes the same proprietary cantharidin-based formulation as VP-102.

2. Pipeline Development

  • Verrica is also exploring the potential of its cantharidin-based therapies for other dermatological conditions, including plantar warts and external genital warts.
  • The company is actively pursuing research and development partnerships to expand its product portfolio and address additional unmet needs in dermatology.

Business Model

Verrica Pharmaceuticals operates on a business model that combines innovative product development with strategic commercialization. The company generates revenue through:

  • Product Sales: Once approved, Verrica plans to commercialize its products directly in the United States and through partnerships in international markets.
  • Licensing Agreements: Verrica has entered into licensing agreements with other pharmaceutical companies to expand the reach of its products. For example, the company has a licensing agreement with Lytix Biopharma for the development of oncolytic peptide-based therapies.
  • Research Collaborations: Verrica collaborates with academic institutions and research organizations to advance its pipeline and explore new therapeutic areas.

Strategic Direction

Verrica Pharmaceuticals is committed to becoming a leader in dermatology therapeutics. Its strategic priorities include:

  • Regulatory Approvals: Securing FDA approval for VP-102 and other pipeline products remains a top priority.
  • Commercialization: Building a robust sales and marketing infrastructure to support the launch of its products in the U.S. and abroad.
  • Pipeline Expansion: Investing in research and development to identify new indications for its existing products and develop novel therapies.
  • Sustainability Goals: Verrica is focused on sustainable manufacturing practices and minimizing its environmental impact.
  • Global Partnerships: Establishing strategic alliances with international pharmaceutical companies to expand its market presence.

Competitive Landscape

Verrica Pharmaceuticals operates in a competitive dermatology market, facing competition from both established pharmaceutical companies and smaller biotech firms. Key competitors include:

  • Novan, Inc.: A clinical-stage biotechnology company focused on nitric oxide-based therapies for dermatological conditions.
  • Dermavant Sciences: A biopharmaceutical company developing innovative therapies for skin diseases.
  • Leo Pharma: A global leader in dermatology with a broad portfolio of products for skin conditions.
  • Bausch Health Companies Inc.: A diversified healthcare company with a strong presence in dermatology.

Despite the competition, Verrica differentiates itself through its focus on cantharidin-based therapies and its proprietary drug-device combination technology.

Risk Factors

Like any pharmaceutical company, Verrica faces several risks, including:

  • Regulatory Risks: Delays or rejections in obtaining FDA approval for its products could impact the company’s growth.
  • Market Dependence: Verrica’s reliance on a limited number of products, such as VP-102, makes it vulnerable to market fluctuations and competitive pressures.
  • Supply Chain Disruptions: The company depends on third-party manufacturers for the production of its products, which could be affected by supply chain issues.
  • Financial Risks: As a clinical-stage company, Verrica has yet to achieve profitability and relies on external funding to support its operations.

Recent Developments

  • FDA Resubmission for VP-102: In 2023, Verrica resubmitted its New Drug Application (NDA) for VP-102 after addressing the FDA’s concerns regarding manufacturing deficiencies.
  • Partnership with Lytix Biopharma: Verrica expanded its pipeline by entering into a licensing agreement with Lytix Biopharma to develop oncolytic peptide-based therapies for dermatological cancers.
  • Clinical Trials: The company initiated Phase 2 clinical trials for VP-103, targeting common warts, and is exploring additional indications for its cantharidin-based therapies.
  • COVID-19 Impact: Verrica experienced delays in clinical trials and regulatory processes due to the pandemic but has since resumed normal operations.

Investment Considerations

Strengths:

  • Innovative Pipeline: Verrica’s focus on cantharidin-based therapies provides a unique competitive advantage.
  • Experienced Leadership: The company’s management team has a proven track record in drug development and commercialization.
  • Market Opportunity: With no FDA-approved treatments for molluscum contagiosum, VP-102 has significant market potential.

Risks:

  • Regulatory Uncertainty: The approval process for VP-102 and other products remains a key risk.
  • Financial Dependence: As a pre-revenue company, Verrica relies on external funding to sustain its operations.
  • Competitive Pressure: The dermatology market is highly competitive, with several established players.

Conclusion

Verrica Pharmaceuticals Inc. is well-positioned to become a leader in dermatology therapeutics, thanks to its innovative pipeline, experienced leadership, and strategic focus. While the company faces challenges such as regulatory risks and financial dependence, its unique approach to addressing unmet needs in dermatology provides a strong foundation for future growth. With the potential approval and commercialization of VP-102, Verrica is poised to make a significant impact in the dermatology market and deliver value to its stakeholders.